Leave message
Can’t find what you’re looking for?
Fill out this form to inquire about our custom protein services!
Inquire about our Custom Services >>
This protein carries a human IgG1 Fc tag at the C-terminus, followed by an Avi tag (Avitag™).
The protein has a calculated MW of 41.4 kDa. The protein migrates as 48-53 kDa when calibrated against Star Ribbon Pre-stained Protein Marker under reducing (R) condition (SDS-PAGE) due to glycosylation.
>90% as determined by SDS-PAGE.
>90% as determined by SEC-MALS.
Lyophilized from 0.22 μm filtered solution in PBS, pH7.4 with trehalose as protectant.
Contact us for customized product form or formulation.
Please see Certificate of Analysis for specific instructions.
For best performance, we strongly recommend you to follow the reconstitution protocol provided in the CoA.
For long term storage, the product should be stored at lyophilized state at -20°C or lower.
Please avoid repeated freeze-thaw cycles.
This product is stable after storage at:
Biotinylated Cynomolgus / Rhesus macaque TIGIT Protein, Fc,Avitag on SDS-PAGE under reducing (R) condition. The gel was stained with Coomassie Blue. The purity of the protein is greater than 90% (With Star Ribbon Pre-stained Protein Marker).
The purity of Biotinylated Cynomolgus / Rhesus macaque TIGIT Protein, Fc,Avitag (Cat. No. TIT-C82F3) is more than 90% and the molecular weight of this protein is around 90-110 kDa verified by SEC-MALS.
Immobilized Biotinylated Cynomolgus / Rhesus macaque TIGIT Protein, Fc,Avitag (Cat. No. TIT-C82F3) at 1 μg/mL (100 μL/well)on streptavidin precoated (STN-N5116) ( can bind Mouse CD155, Mouse IgG2a Fc Tag (Cat. No. CD5-M5254) with a linear range of 0.004-0.125 μg/mL (QC tested).
Price(USD) : $350.00
Price(USD) : $1380.00
Price(USD) : $32.00
Price(USD) : $137.00
Price(USD) : $50.00
Price(USD) : $120.00
Price(USD) : $138.00
Price(USD) : $230.00
Emerging VoCs, Omicron, Delta, Beta, Alpha mutants and so on, including RBD, S trimer, S1, NTD, NP, etc. These mutants are of high purity and bioactivity and can be used to evaluate the efficacy of the antibodies and vaccination.
ACROBiosystems developed a series of GMP grade cytokines under the GMP grade quality management system. Those products are all suitable for T/NK cell generation, activation, and proliferation in cell therapy research.
50+ targets designed for CAR detection, including PE/FITC/biotin labeled proteins. The key reagents for CD19 and BCMA were FDA DMF filed which can support your IND, NDA and BLA process.
GMP grade cytokines, reagents for cell activation, gene edition, DNA/RNA removal, etc. Particularly focus on product design, quality control and solution-based support to link each phase of your cell and gene therapy journey.
Full length multi-pass TPs with stabilized structure and high bioactivity for immunization, antibody screening, cell based assay and CAR detection, including hot CD20, Claudin 18.2, CD133, GPRC5D,CCR8, CCR5, etc.
CD3 proteins and a collection of for bispecific antibody development which are of high specificity and bioactivities and suitable for immunization, antibody screening.
A series of immune checkpoints including classic co-inhibitory and co-stimulatory receptors. The comprehensive catalog contains 100+ targets with various species and tags, and the high-quality proteins are in good batch-to-batch consistency.
To meet the needs of ADCs development, ACROBiosystems can provide: A variety of high-quality target proteins; MMPs/Cathepsin/uPA for cleavable linker; Anti-payload antibodies & anti-idiotypic antibodies for immunogenicity and PK analysis; SPR/BLI analytical and ADA development service.
Comprehensive collection of Fc receptor proteins, including their common variants, which can help expedite your antibody development.
The MABSOL biotinylated protein collection includes more than a hundred commonly studied drug targets and biomarker proteins.
Comprehensive cytokines including IL families, growth factors, chemokines, TNFs, etc. These products are HEK293 expressed and nearly in authentic structure, high purity and bioactivity, cell based assay/SPR/BLI verified.
To support preclinical/clinical immunogenicity and PK analysis, ACROBiosystems has developed a series of high-affinity anti-idiotypic antibodies. Our pipeline covers five hot targets including adalimum*b, rituxim*b, cetuxim*b, trastuzum*b, and bevacizum*b.
English Name | Research Code | Research Phase | Company | First Brand Name | First Approved Country | First Indication | First Approved Company | First Approved Date | Indications | Clinical Trials |
---|
English Name | Research Code | Research Phase | Company | Indications | Clinical Trials |
---|---|---|---|---|---|
PM-1022 | PM-1022 | Phase 1 Clinical | Biotheus Inc | Neoplasms | Details |
BAT-6005 | BAT-6005 | Phase 1 Clinical | Bio-Thera Solutions Ltd | Solid tumours | Details |
ZG-005 | ZG-005 | Phase 2 Clinical | Suzhou Zelgen Biopharmaceuticals Co Ltd | Solid tumours | Details |
SHS-006(Nanjing Sanhome Pharmaceutical) | SHS-006; SH-006; SH006 | Phase 1 Clinical | Nanjing Sanhome Pharmaceutical Co Ltd | Solid tumours | Details |
BAT-6021 | BAT6021; BAT-6021 | Phase 1 Clinical | Bio-Thera Solutions Ltd | Solid tumours | Details |
DW-2008 | DW-2008; DW-2008S | Phase 1 Clinical | Dong Wha Pharm Co Ltd | Coronavirus Disease 2019 (COVID-19); Rhinitis, Allergic; Asthma | Details |
HB0030 | HB-0030 | Phase 1 Clinical | Huabo Biopharm Co Ltd, Shanghai Huaota Biopharmaceutical Co Ltd | Solid tumours | Details |
HH-101 | HH-101 | Phase 1 Clinical | Huahui Health Ltd | Solid tumours | Details |
SEA-TGT | SGN-TGT; SEA-TGT; SGN-TIGIT | Phase 1 Clinical | Seattle Genetics Inc | Lymphoma, T-Cell, Peripheral; Ovarian Neoplasms; Skin Melanoma; Stomach Neoplasms; Squamous Cell Carcinoma of Head and Neck; Esophageal Neoplasms; Lymphoma, Large B-Cell, Diffuse; Hodgkin Disease; Triple Negative Breast Neoplasms; Urinary Bladder Neoplasms; Uterine Cervical Neoplasms; Carcinoma, Non-Small-Cell Lung | Details |
SHR-2002 | SHR-2002 | Phase 1 Clinical | Suzhou Suncadia Biopharmaceuticals Co Ltd, Shanghai Hengrui Pharmaceutical Co Ltd | Neoplasms | Details |
M-6223 | M-6223 | Phase 1 Clinical | Emd Serono Inc, Merck Serono | Solid tumours | Details |
JS-006 | JS-006; TAB-006; CHS-006 | Phase 1 Clinical | Shanghai Junshi Biosciences Co Ltd | Solid tumours; Neoplasms | Details |
Domvanalimab | AB-154 | Phase 3 Clinical | Arcus Biosciences Inc, Gilead Sciences Inc | Solid tumours; Glioblastoma; Lung Neoplasms; Carcinoma, Squamous Cell; Carcinoma, Non-Small-Cell Lung; Melanoma; Gastrointestinal Neoplasms | Details |
AZD-2936 | AZD-2936 | Phase 2 Clinical | Astrazeneca Plc | Carcinoma, Non-Small-Cell Lung | Details |
HB-0036 | HB-0036 | Phase 2 Clinical | Huabo Biopharm Co Ltd | Solid tumours; Carcinoma, Non-Small-Cell Lung | Details |
BC008-1A | BC008-1A | Phase 1 Clinical | Sichuan Luzhou Buchang Biopharmaceutical Co Ltd | Solid tumours | Details |
PM-1021 | PM1021 | Phase 1 Clinical | Biotheus Inc | Solid tumours; Neoplasms | Details |
HLX-53 | HLX-53 | Phase 1 Clinical | Shanghai Henlius Biologics Co Ltd | Solid tumours; Lymphoma | Details |
Recombinant humanized anti-TIGIT monoclonal antibody(Lepu biopharma) | LP-010 | Phase 1 Clinical | Lepu Biotech Co Ltd | Solid tumours | Details |
HLX-301 | HLX-301 | Phase 2 Clinical | Shanghai Henlius Biologics Co Ltd | Solid tumours; Neoplasms; Lymphoma; Neoplasm Metastasis; Carcinoma, Non-Small-Cell Lung | Details |
AK-127 | AK-127 | Phase 1 Clinical | Zhongshan Akeso Biopharma Co Ltd | Solid tumours; Neoplasms | Details |
ASP-8374 | ASP-8374; PTZ-201 | Phase 1 Clinical | Potenza Therapeutics, Astellas Pharma Inc | Solid tumours; Neoplasms; Glioblastoma | Details |
Tamgiblimab | IBI-939 | Phase 1 Clinical | Innovent Biologics(Suzhou) Co Ltd | Neoplasms; Lung Neoplasms | Details |
PM-1009 | PM1009 | Phase 1 Clinical | Biotheus Inc | Solid tumours; Neoplasms; Lung Neoplasms | Details |
HL-301 | HL-301 | Phase 2 Clinical | Hanlim Pharm Co Ltd | Radiation Pneumonitis; Lung Neoplasms | Details |
Belrestotug | EOS-448; EOS-884448; GSK-4428859; GSK-4428859A | Phase 2 Clinical | Iteos | Head and Neck Neoplasms; Neoplasms; Multiple Myeloma; Lung Neoplasms; Carcinoma, Non-Small-Cell Lung; Melanoma | Details |
AK-130 | AK-130 | Phase 1 Clinical | Zhongshan Akeso Biopharma Co Ltd | Neoplasms | Details |
AGEN-1777 | AGEN-1777; BMS-986442 | Phase 2 Clinical | Agenus Inc | Solid tumours; Neoplasms; Carcinoma, Non-Small-Cell Lung | Details |
BMS-986207 | BMS-986207 | Phase 2 Clinical | Bristol-Myers Squibb Company | Solid tumours; Head and Neck Neoplasms; Ovarian Neoplasms; Endometrial Neoplasms; Carcinoma, Non-Small-Cell Lung | Details |
Vibostolimab | MK-7684 | Phase 3 Clinical | Merck Sharp & Dohme Corp | Solid tumours; Small Cell Lung Carcinoma; Carcinoma, Non-Small-Cell Lung; Melanoma | Details |
Pembrolizumab/Vibostolimab | MK-7684A | Phase 3 Clinical | Merck & Co Inc | Ovarian Neoplasms; Hematologic Neoplasms; Squamous Cell Carcinoma of Head and Neck; Stomach Neoplasms; Esophageal Neoplasms; Small Cell Lung Carcinoma; Triple Negative Breast Neoplasms; Neoplasms; Urinary Bladder Neoplasms; Cholangiocarcinoma; Endometrial Neoplasms; Gallbladder Neoplasms; Lung Neoplasms; Carcinoma, Non-Small-Cell Lung; Carcinoma, Hepatocellular; Uterine Cervical Neoplasms | Details |
Tiragolumab | RG-6058; MTIG-7192A; RO-7092284 | Phase 3 Clinical | F. Hoffmann-La Roche Ltd | Carcinoma, Transitional Cell; Hemangioendothelioma, Epithelioid; Neoplasm Metastasis; Melanoma; Carcinoma, Non-Small-Cell Lung; Adenocarcinoma; Uterine Cervical Neoplasms; Lymphoma, Non-Hodgkin; Esophageal Squamous Cell Carcinoma; Sarcoma; Lymphoma, Follicular; Multiple Myeloma; Carcinoma, Medullary; Chordoma; Liver Neoplasms; Triple Negative Breast Neoplasms; Neoplasms; Small Cell Lung Carcinoma; Carcinoma, Renal Cell; Rhabdoid Tumor; Stomach Neoplasms; Squamous Cell Carcinoma of Head and Neck; Rectal Neoplasms; Esophageal Neoplasms; Head and Neck Neoplasms; Lymphoma, B-Cell; Solid tumours; Teratoma | Details |
Ociperlimab | BGB-A1217 | Phase 3 Clinical | Beigene Ltd | Solid tumours; Biliary Tract Neoplasms; Esophageal Neoplasms; Lymphoma, Large B-Cell, Diffuse; Small Cell Lung Carcinoma; Cholangiocarcinoma; Nasopharyngeal Carcinoma; Esophageal Squamous Cell Carcinoma; Carcinoma, Non-Small-Cell Lung; Uterine Cervical Neoplasms; Carcinoma, Hepatocellular | Details |
IBI-321 | IBI-321 | Phase 1 Clinical | Innovent Biologics(Suzhou) Co Ltd | Solid tumours; Neoplasms | Details |
AB-308 | AB-308 | Phase 1 Clinical | Arcus Biosciences Inc | Solid tumours; Esophageal Neoplasms; Stomach Neoplasms; Lymphoma, Large B-Cell, Diffuse; Multiple Myeloma; Lymphoma, Non-Hodgkin; Melanoma; Adenocarcinoma; Carcinoma, Non-Small-Cell Lung; Uterine Cervical Neoplasms | Details |
COM-902 | COM-902 | Phase 1 Clinical | Compugen Ltd | Ovarian Neoplasms; Squamous Cell Carcinoma of Head and Neck; Colonic Neoplasms; Neoplasms; Multiple Myeloma; Neoplasms, Plasma Cell; Lung Neoplasms | Details |
Etigilimab | OMP-313M32 | Phase 2 Clinical | Oncomed Pharmaceuticals Inc | Solid tumours; Neoplasms; Neoplasm Metastasis | Details |
This web search service is supported by Google Inc.